TY - JOUR
T1 - The effect of low-dose aspirin on platelet function during pregnancy compared to placebo
T2 - An explorative study
AU - Bij de Weg, Jeske M.
AU - Landman, Anadeijda J. E. M. C.
AU - de Vries, Johanna I. P.
AU - Thijs, Abel
AU - Harmsze, Ankie M.
AU - Oudijk, Martijn A.
AU - de Boer, Marjon A.
N1 - Funding Information: This research did not receive any specific grant from funCcies in the public, commercial, or not-for-profit sectors. The original APRIL study received funding from ZonMw, The Dutch Organization for Health Research and Development (Grant No 836041006 ). Funding Information: In this explorative study, we performed platelet function tests in a subset of APRIL study participants. The APRIL study was a multicentre double-blind placebo-controlled randomized trial assessing the effect of aspirin 80 mg once daily on the prevention of recurrent preterm birth [17] . The APRIL study was funded by ZonMw, The Dutch Organization for Health Research and Development (Grant No 836041006), and registered in the Dutch Clinical Trial Registry (NL5553, NTR5675). The study protocol and trial results have been described in detail previously [17,18] . Publisher Copyright: © 2022 The Author(s)
PY - 2022/11/1
Y1 - 2022/11/1
N2 - OBJECTIVES: To evaluate the effect of aspirin 80 mg compared to placebo on platelet function tests in the second and third trimester of pregnancy. STUDY DESIGN: An explorative study was performed to assess laboratory platelet function in a subpopulation of the APRIL trial: a randomized double-blind trial comparing aspirin 80 mg once daily to placebo for the prevention of recurrent preterm birth. Platelet function was measured between 18 and 22, and between 28 and 32 weeks gestational age with three platelet function tests: VerifyNow®, Chronolog light transmission aggregometry (Chronolog LTA) and serum thromboxane B2 (TxB2). Medication adherence was evaluated by pill counts, self-reported diaries and structured interviews. RESULTS: We included 11 women, six in the aspirin and five in the placebo group. In women receiving aspirin, platelet function was significantly lower compared to women receiving placebo for all three tests: VerifyNow® Aspirin Reaction Units (450.5 vs 648.0, p = 0.017); Chronolog LTA (9.5% vs 94.5%, p = 0.009); serum TxB2 levels (11.9 ng/mL versus 175.9 ng/mL, p = 0.030). For all three tests, platelet function did not differ between the second and third trimester of pregnancy in the aspirin group. In the placebo group, serum TxB2 levels were significantly higher in the third trimester. One non-adherent participant in the aspirin group showed results similar to the placebo group. CONCLUSION: Aspirin 80 mg has a clear inhibitory effect on laboratory platelet function during pregnancy compared to placebo. This effect is similar in the second and third trimester of pregnancy.
AB - OBJECTIVES: To evaluate the effect of aspirin 80 mg compared to placebo on platelet function tests in the second and third trimester of pregnancy. STUDY DESIGN: An explorative study was performed to assess laboratory platelet function in a subpopulation of the APRIL trial: a randomized double-blind trial comparing aspirin 80 mg once daily to placebo for the prevention of recurrent preterm birth. Platelet function was measured between 18 and 22, and between 28 and 32 weeks gestational age with three platelet function tests: VerifyNow®, Chronolog light transmission aggregometry (Chronolog LTA) and serum thromboxane B2 (TxB2). Medication adherence was evaluated by pill counts, self-reported diaries and structured interviews. RESULTS: We included 11 women, six in the aspirin and five in the placebo group. In women receiving aspirin, platelet function was significantly lower compared to women receiving placebo for all three tests: VerifyNow® Aspirin Reaction Units (450.5 vs 648.0, p = 0.017); Chronolog LTA (9.5% vs 94.5%, p = 0.009); serum TxB2 levels (11.9 ng/mL versus 175.9 ng/mL, p = 0.030). For all three tests, platelet function did not differ between the second and third trimester of pregnancy in the aspirin group. In the placebo group, serum TxB2 levels were significantly higher in the third trimester. One non-adherent participant in the aspirin group showed results similar to the placebo group. CONCLUSION: Aspirin 80 mg has a clear inhibitory effect on laboratory platelet function during pregnancy compared to placebo. This effect is similar in the second and third trimester of pregnancy.
UR - http://www.scopus.com/inward/record.url?scp=85140417316&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.ejogrb.2022.08.025
DO - https://doi.org/10.1016/j.ejogrb.2022.08.025
M3 - Article
C2 - 36116392
SN - 0301-2115
VL - 278
SP - 67
EP - 71
JO - European journal of obstetrics, gynecology, and reproductive biology
JF - European journal of obstetrics, gynecology, and reproductive biology
ER -